Retatrutide vs Tirzepatide vs Semaglutide: One, Two or Three Receptors

Last updated August 13, 2026

Semaglutide, tirzepatide and retatrutide are the three most discussed molecules in metabolic research, and the difference between them can be counted on one hand: one receptor, two receptors, three receptors. This page compares their mechanisms, their published evidence and their regulatory positions from a laboratory perspective. Everything summarised below comes from pharmaceutical trials of authorised or investigational medicines; none of it is a statement about research reagents, and nothing on this page is medical advice.

What are semaglutide, tirzepatide and retatrutide?

Semaglutide is a GLP-1 receptor agonist, a modified analogue of the human incretin hormone GLP-1 with a fatty-acid chain that extends its half-life to about a week. It is the reference molecule of the class, with the largest clinical evidence base of any peptide in current use, and it is a research benchmark rather than a catalog item here.

Tirzepatide is a 39-amino-acid dual agonist that activates both the GLP-1 receptor and the GIP receptor. It was the first dual incretin agonist to reach the published clinical literature, and its trial programme made the case that adding a second receptor changes the size of the effect, not just its pharmacology.

Retatrutide (LY3437943) extends the same logic one step further: a triple agonist of the GLP-1, GIP and glucagon receptors. It is the newest of the three and the only one still entirely investigational, with its phase 3 programme in progress.

How do their mechanisms differ?

All three molecules share the GLP-1 receptor arm: enhanced glucose-dependent insulin secretion, slowed gastric emptying and central appetite signalling. Tirzepatide adds GIP receptor agonism, which in preclinical work modulates insulin sensitivity and adipose tissue biology, and appears to blunt some GLP-1 side effects at the receptor-signalling level. Retatrutide adds a third arm, glucagon receptor agonism, which is the mechanistically distinct one: glucagon receptor activity raises energy expenditure and hepatic lipid turnover, so the triple agonist works on both sides of the energy balance equation rather than only on intake.

For receptor pharmacology work this makes the three molecules a natural graded series: the same backbone concept sampled at one, two and three receptors, with selectivity and potency differences documented compound by compound in the published literature.

What does the published clinical evidence show?

The three landmark obesity trials give the cleanest side-by-side reading, with the caveat that they differ in duration and population and are not head-to-head comparisons. In STEP 1, the investigators reported a mean weight reduction of 14.9 percent at 68 weeks with semaglutide 2.4 mg weekly, against 2.4 percent with placebo. In SURMOUNT-1, tirzepatide at the highest dose was reported to produce up to 20.9 percent mean reduction at 72 weeks. In the phase 2 obesity trial of retatrutide, the authors reported up to 24.2 percent mean reduction at 48 weeks at the highest dose, with the phase 3 TRIUMPH programme still under way.

Read as a series, the pattern the literature suggests is that each added receptor arm has so far come with a larger reported effect size, at the price of less accumulated evidence: semaglutide has years of outcome data, tirzepatide has completed pivotal trials, retatrutide has a single published phase 2 and an ongoing phase 3.

Which research applications does each suit?

In laboratory settings the three molecules are used as receptor pharmacology tools: single, dual and triple agonism against the same receptor family makes them well suited to comparative signalling studies, receptor selectivity assays and incretin biology models. Retatrutide is the natural probe for questions about glucagon receptor co-activation; tirzepatide for GIP receptor contribution; semaglutide as the single-receptor control. The published literature on each compound describes the assay systems in which it has been characterised, and that literature, not this page, should drive experimental design.

What is the regulatory status?

Semaglutide and tirzepatide are the active substances of authorised medicines in the EU and the US. Retatrutide has no marketing authorisation anywhere; it is an investigational compound. Research material supplied under a research use only framework is not any of those medicinal products, is not a medicine, and is not for human or veterinary use. None of the three currently appears by name on the WADA Prohibited List sections covering peptide hormones and releasing factors, but the live list is the only authority worth citing and athletes are responsible for checking it.

Research sourcing and quality checks

For laboratory procurement, the practical questions are documentation questions. Both retatrutide and tirzepatide are available in our catalog as research reagents; where a batch has been tested, its report is published in the lab reports archive and linked from the product page. Our guide on how to read a certificate of analysis covers what that documentation should contain, and our evidence-tier ranking places all three molecules in the wider research landscape.

Conclusion

One receptor, two, three: the incretin series is the clearest natural experiment in current metabolic research, and the published numbers so far scale with the receptor count while the depth of evidence runs the other way. For research buyers the summary is simple: semaglutide is the benchmark, tirzepatide the documented dual agonist, retatrutide the investigational triple with the steepest published curve and the youngest evidence base.

References

• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM 2021. PubMed · NCT03548935
• Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022. PubMed · NCT04184622
• Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, a Phase 2 Trial. NEJM 2023. PubMed · NCT04881760